Affording Hope: Paying for Multimillion-Dollar Cell and Gene Therapies

Angela Garcia, FSA, CERA, MAAA MAAC – November 15<sup>th</sup>, 2023



©2021 ARTHUR J. GALLAGHER & CO



Agenda

What are Cell & Gene Therapies?

Why are they important?


Currently available and pipeline therapies

The role of the Actuary in assessing the risk

Payer concerns and potential solutions



### What are Cell & Gene Therapies?



- <u>Gene therapy</u> involves altering one's genes in effort to treat or stop disease either inside the body (in vivo) or outside of the body (ex vivo).
- <u>Cell therapy</u> is the injecting, engrafting, or implanted use of viable cells into a patient to receive a medicinal effect

NIH U.S. National Library of Medicine


Sources: <u>https://medlineplus.gov/genetics/understanding/therapy/procedures/</u> <u>Gene therapy - Mayo Clinic</u>



### Why do we need these therapies?

# RARE DISEASES: MORE COMMON THAN YOU THINK?

Rare diseases are defined as those affecting a small percentage of a population – fewer than 200,000 in the U.S. and fewer than 1 in 2,000 in Europe





## **Cell & Gene Therapy Implications**


#### • These are potentially life-saving or life-altering therapies

- Patients with rare diseases could live without the need for ongoing treatments or the burden of daily disease management after a single course of treatment
- Primary challenges:
  - Cost/benefit mismatch
    - Large upfront cost with benefits (lower lifetime treatment cost, societal benefits) accruing over time
    - Patient may not stay with same payer that covered the therapy
  - Uncertainty over exposure
    - Who qualifies based on inclusion criteria and who will want the drug
  - Difficult to track outcomes across different payers/healthcare systems
  - Concerns over long-term durability and patient safety
  - Patient access (need to travel to a QTC qualified treatment center)



### What's Available Today?

#### **CELL AND GENE THERAPIES IN THE US AND EU MARKETS**



joanna-sadowska-phd Source: CAT quarterly highlights and approved ATMPs - May 2023

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

Typical Cell Therapy Cost: \$300-500K drug, + administration Typical Gene Therapy Cost: \$500K-**\$3.5M** + administration

## The Top 6 Most Expensive Drugs in the World are All Gene Therapies



#### #1: Hemgenix Company: CSL Behring, uniQure • Disease: Hemophilia B Dystrophy Cost per Dose: \$3.5 million

• Approved: Nov 2022

#### #2: Elevidys

- Company: Sarepta Therapeutics
- Disease: Duchenne Muscular
- Cost per Dose: \$3.2 million
- Approved: Jun 2023

#### #3: Skysona

- Company: Bluebird Bio
- Disease: Cerebral Adrenoleukodystrophy
- Cost per Dose: \$3 million
- Approved: Sep 2022

#### #4: Roctavian

- Company: BioMarin
- Disease: Hemophilia A
- Cost per Dose: \$2.9 million
- Approved: June 2022

#### #5: Zynteglo

- Company: Bluebird Bio
- Disease: Transfusion-dependent Thalassemia
- Cost per Dose: \$2.8 million
- Approved: Sep 2022


#### #6: Zolgensma

- Company: Novartis
- Disease: Spinal Muscular Atrophy
- Cost per Dose: \$2.1 million
- Approved: May 2019




### Cell & Gene Therapy Pipeline

# of Approvals



	2021	2022	2023	2024	2025	2030
Cancer, hematological	6.0	6.8	8.0	9.8	11.7	31.6
Cancer, solid tumor	0.0	0.4	0.9	1.4	2.0	4.1
Cardiovascular	0.0	0.0	0.0	0.0	0.0	0.2
Hematology	0.0	1.6	2.9	4.2	5.2	9.1
Immunological	0.0	0.1	0.3	0.5	0.6	1.4
Metabolic	0.0	0.2	0.5	0.6	0.9	3.1
Musculoskeletal	0.0	0.1	0.2	0.2	0.4	1.0
Neurological	1.0	1.3	1.8	2.2	2.5	3.7
Ophthalmological	2.0	2.8	3.3	4.1	4.5	6.2
Other	0.0	0.4	0.9	1.6	1.9	3.1
Total	9.0	13.6	18.7	24.7	29.7	63.5

Projected Revenue (billions)




**Pipeline Product Indications:** 

- #1: Hematological cancers
- #2: Hematology
- #3: Ophthalmological

**Source:** Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues - ScienceDirect



#### **Gene Therapy Pipeline**






#### **Cell Therapy Pipeline**

#### Allogeneic CAR-T

(40 Preclinical Assets)





## A Case Study in Uncertainty: Sickle Cell

## Exa-Cel

- Vertex/CRISPR
- First US marketed CRISPR therapy if/once approved
- Ex-Vivo therapy utilizing Cas9 gene editing

## Lovo-Cel

- Bluebird Bio
- Ex-Vivo therapy using a lentiviral vector encoding a modified betaglobin gene into an autologous transplanted hematopoietic stem cell to produce anti-sickling hemoglobin



Timing:	• Dec 8, 2023 & Dec 20, 2023				
Target Population:	<ul> <li>Anticipating ~42,500 potential candidates aged 12 and older, the majority of which are of African descent</li> </ul>				
Target Price:	• \$1.4M-\$3.0M for drug cost alone				



## Actuarial Challenges in Quantification

### Frequency


- Starting point: Use population incidence/prevalence to estimate risk
  - This could vary significantly by type of medical coverage (Commercial, Medicare, Medicaid) as well as geography
  - For example, 1/3 of sickle cell patients are in the commercial population, the other 2/3 in Medicaid programs
- ICD-10 codes for claimants (Sickle-cell disorders: D57-) can give indication within specific population of who may be eligible
- Specific clinical criteria needs to be met; having the disease is usually not enough to qualify for the therapy
- Watch pipeline closely for changes in approval dates, FDA rejections, or changes in clinical indications

The biggest unknown of all: human behavior

## **Geographical Considerations**




Sickle Cell Patient Prevalence in Medicaid



Source: Quantile Health

## **Example Treatment Pathway**





#### ZYNTEGLO Can Only Be Administered at a Qualified Treatment Center (QTC)

Source: AMS University (elasticvirtual.com)

1



## Actuarial Challenges in Quantification

## Severity

- Two components: the drug cost itself and the administrative costs
  - In vivo: "go in, get a shot."
  - Ex vivo: "cells are extracted, modified, and reinserted." Much more expensive due to higher admin costs/inpatient stays
- Other considerations: discounts (340B rebates), hospital billing practices, complications, cost offsets (i.e., a hemophiliac no longer needing expensive factor drug), patient travel, time off from work
- Cost of drug is often not known until day of approval, sometimes even later



## **Current Solutions in the Market**

#### Payer reinsurance/stop-loss/carve-out

- Carve out of financial responsibility or risk for specified cell and/or gene therapies
- Available as stand-alone products or incorporated into existing specific/aggregate/ASD coverage
- No performance guarantees

#### Contract negotiation & data management services

- Act as third parties to negotiate contracts for cell and gene therapies, and provide data/outcomes tracking services
- Contracts may include performance guarantees, but the service company themselves do not assume financial risk

#### Provider contract negotiation

- Oriented towards providers and patient care pathways
- Multiple services offered, including COE network creation and contracting, data analytics and cost containment
- Performance guarantees are oriented towards clinical services and outcomes rather than financial guarantees

#### Financial and pharma company warranty services

 Include payment plans, with or without performance guarantees, and warranties for purchase by pharmaceutical companies that can provide protection to payers for suboptimal product performance



#### **Concerns for Carriers/Health Plans**

Company	RISK			COST		ADMINISTRATION		PATIENT/PROVIDER		
Product	Actuarial/ financial	Performance	Payment timing	Product	Ancillary	Data tracking	Contracts	COE access	Patient access	Patient care
Payer reinsurance/stop-lo	ss/carve-out									
BCS Financial Stop-Loss Gene Therapy	•		•	•	•					
CVS Health Gene Therapy Stop-Loss	•			•	•				•	
Evernorth Embarc Benefit Protection Program	•	•	•	•	•	•	•	•	•	•
MedImpact Healthcare Systems MedShield	•			•					•	
<b>OptumRx</b> Optum Gene Therapy Risk Protection	•	•	•	•		•	•		•	•
OutcomeRx Patient Access to Costly and Curative Therapies	•		•	•		•			•	
PayRx PayRx Benefit Protection	•	•	•	•	•	•				
Contract negotiation & da	ta manageme	nt services for pa	ayers and pha	rma companie	s					
Audaire Health Gene & Cell Therapy		•	•	•		•	•			
Outcomes Management Service										

Sources: https://newdigs.mit.edu/sites/default/files/FoCUS-WP-CGT-Market-Solutions.pdf;

https://www.medimpact.com/resources/client-news/surprising-impact-gene-therapies



### **Concerns for Carriers/Health Plans**

<b>Company</b> Product		RISK		cc	DST	ADMINIS	STRATION	PAT	IENT/PROV	IDER
FIGUUGL	Actuarial/ financial	Performance	Payment timing	Product	Ancillary	Data tracking	Contracts	COE access	Patient access	Patient care
Real Endpoints	•	•		•		•	•		•	
RE Marketplace										
Provider contract negotiat	tion									
BlueCross Blue Shield		•	•	•	•	•	•	•	•	•
Association										
Blue Distinction Center for										
Cellular Immunotherapy										
Emerging Therapy	•		•	•	•	•	•	٠		
Solutions										
ETS Programs of										
Excellence,										
ETS Analytics &										
ETS Buyer's Group										
Financial and pharma com	pany warrant	y services								
August Care	•	•	•	•		•	•	•	•	•
Outcomes-based Financial										
Solutions										
CVS Health			•	•					•	
Gene Therapy Payment										
Plan										
OutcomeRx		•				•	•		•	
Specialty Therapy										
Warranty										

Sources: https://newdigs.mit.edu/sites/default/files/FoCUS-WP-CGT-Market-Solutions.pdf; https://www.medimpact.com/resources/client-news/surprising-impact-gene-therapies



### What Comes Next?

Figure 1. FoCUS precision financing solutions and their ability to address key challenges associated with cell and gene therapies

Blue circles represent the proportion of the associated challenge (payment timing, performance, actuarial risk) addressed by the precision financing solution. A full blue circle indicates the challenge is fully addressed; an empty circle indicates the solution has not addressed the challenge.

		Payment timing	Performance	Actuarial risk
Milestone-based contracts				$\bigcirc$
Warranty	$\bigotimes$			$\bigcirc$
Performance- based annuities	*/5			
ORBM and risk pools				
Subscription model	Subscribe		$\bigcirc$	

#### No single solution checks all the boxes

Source: <u>https://newdigs.tuftsmedicalcenter.org/wp-</u> content/uploads/2022/06/FoCUS-WP-CGT-Market-Solutions.pdf



## Q&A



## Thank you!



©2021 ARTHUR J. GALLAGHER & CC



### General Disclaimer for all Analytical Work

This analysis has been prepared by Gallagher Re on the condition that it shall be treated as strictly confidential and shall not be communicated in whole, in part, or in summary to any third party without prior written consent from Gallagher Re. Gallagher Re is a business unit that includes a number of subsidiaries and affiliates of Arthur J. Gallagher & Co. which are engaged in the reinsurance intermediary and advisory business. All references to Gallagher Re below, to the extent relevant, include the parent and applicable affiliate companies of Gallagher Re.

Gallagher Re has relied upon data from public and/or other sources when preparing this analysis. No attempt has been made to verify independently the accuracy of this data. Gallagher Re does not represent or otherwise guarantee the accuracy or completeness of such data nor assume responsibility for the result of any error or omission in the data or other materials gathered from any source in the preparation of this analysis. Gallagher Re shall have no liability in connection with any results, including, without limitation, those arising from based upon or in connection with errors, omissions, inaccuracies, or inadequacies associated with the data or arising from, based upon or in connection with any results contained herein. Gallagher Re expressly disclaims any and all liability, based on any legal theory, arising from, based upon or in connection with this analysis. Gallagher Re assumes no duty in contract, tort or otherwise to any party arising from, based upon or in connection with this analysis, and no party should expect Gallagher Re to owe it any such duty.

There are many uncertainties inherent in this analysis including, but not limited to, issues such as limitations in the available data, reliance on client data and outside data sources, the underlying volatility of loss and other random processes, uncertainties that characterize the application of professional judgment in estimates and assumptions. Ultimate losses, liabilities and claims depend upon future contingent events, including but not limited to unanticipated changes in inflation, laws, and regulations. As a result of these uncertainties, the actual outcomes could vary significantly from Gallagher Re's estimates in either direction. Gallagher Re makes no representation about and does not guarantee the outcome, results, success, or profitability of any insurance or reinsurance program or venture, whether or not the analyses or conclusions contained herein apply to such program or venture.

Gallagher Re does not recommend making decisions based solely on the information contained in this analysis. Rather, this analysis should be viewed as a supplement to other information, including specific business practice, claims experience, and financial situation. Independent professional advisors should be consulted with respect to the issues and conclusions presented herein and their possible application.

Gallagher Re makes no representation or warranty as to the accuracy or completeness of this document and its contents.

This analysis is not intended to be a complete actuarial communication, and as such is not intended to be relied upon. A complete communication can be provided upon request. Subject to all terms of this Disclaimer, Gallagher Re actuaries are available to answer questions about this analysis.

Gallagher Re does not provide legal, accounting, or tax advice. This analysis does not constitute, is not intended to provide, and should not be construed as such advice. Qualified advisers should be consulted in these areas.

Gallagher Re makes no representation, does not guarantee and assumes no liability for the accuracy or completeness of, or any results obtained by application of, this analysis and conclusions provided herein.

Where data is supplied by way of CD or other electronic format, Gallagher Re accepts no liability for any loss or damage caused to the Recipient directly or indirectly through use of any such CD or other electronic format, even where caused by negligence. Without limitation, Gallagher Re shall not be liable for: loss or corruption of data, damage to any computer or communications system, indirect or consequential losses. The Recipient should take proper precautions to prevent loss or damage – including the use of a virus checker.

This limitation of liability does not apply to losses or damage caused by death, personal injury, dishonesty or any other liability which cannot be excluded by law.

This analysis is not intended to be a complete Financial Analysis communication. A complete communication can be provided upon request. Subject to all terms of this Disclaimer, Gallagher Re analysts are available to answer questions about this analysis.

Gallagher Re does not guarantee any specific financial result or outcome, level of profitability, valuation, or rating agency outcome with respect to AM Best or any other agency. Gallagher Re specifically disclaims any and all liability for all damages of any amount or any type, including without limitation, lost profits, unrealized profits, compensatory damages based on any legal theory, punitive, multiple or statutory damages or fines of any type, based upon, arising from, in connection with or in any manner related to the services provided hereunder.

Acceptance of this document shall be deemed agreement to the above.

Gallagher Re is a trading name of Arthur J. Gallagher (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. Registered Office: The Walbrook Building, 25 Walbrook, London EC4N 8AW. Registered in England and Wales. Company Number: 1193013. www.ajg.com/uk

Gallagher Re is a trading name of Nordic Försäkring & Riskhantering AB ("Nordic"). Nordic is authorised by the Swedish Financial Supervisory Authority, and incorporated in Sweden under company number 556418-5014 with registered address at Mölndalsvägen 22, 412 63 Göteborg, Sweden. Nordic also offers and performs insurance distribution services/activities through its Belgian branch. The Belgian branch has its registered office at Posthofbrug 6-8 bus 5/134, 2600 Berchem, company number 0743.567.257. Nordic is also deemed authorised and regulated by the UK Financial Conduct Authority under the Temporary Permissions Regime. UK branch registered in England and Wales under branch number BR021003, with registered address at The Walbrook Building, 25 Walbrook, London EC4N 8AW.